Back to search results

Study of 177Lu Girentuximab, Cabozantinib, and Nivolumab for Advanced Clear Cell Kidney Cancer

This study is testing a combination of three drugs – 177Lu girentuximab, cabozantinib, and nivolumab – for people with advanced clear cell renal cell carcinoma (a type of kidney cancer) who haven't received prior treatment. Researchers want to see if this combination is safe and how well it helps control the cancer. You might be able to join if you are at least 18 years old, have advanced clear cell kidney cancer, and have at least one measurable tumor. The main goal is to track any side effects, and also to see how many participants experience a complete disappearance of their cancer.

Study design
This is an interventional study planning to enroll 100 participants. It is not specified if it is randomized or blinded.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Adverse events will be measured through study completion, which is an average of 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05663710

Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC

Recruiting
PHASE1Ages 18+InterventionalTreatment
M.D. Anderson Cancer Center
~100 participants
Updated 2026-07-30 on ClinicalTrials.gov
What's tested:177Lu girentuximabNivolumabCabozantinibArabinoFuranosylGuanine [18F]F-AraG

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Measured over through study completion; an average of 1 year

Conditions

Advanced Cancer
Clear Cell Renal Cell Carcinoma

Explore related trials

Clear Cell Renal Cell Carcinoma

NCT05663710

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • MD Anderson Cancer Center

    Houston, Texasstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Eric Jonasch, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center

Who to contact

Eric Jonasch, MD
[email protected]
(713) 563-7232
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0through study completion; an average of 1 year